Platelets and diabetes: A complex association

References

• Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010;7:251–259
   PubMed Web of Science ®Google Scholar
• Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983;32:217–221
   PubMedGoogle Scholar
• Mikhailidis DP, Mikhailidis AM, Barradas MA, Dandona P. Effect of nonesterified fatty acids on the stability of prostacyclin activity. Metabolism 1983;32:717–721
   PubMedGoogle Scholar
• Barradas MA, Mikhailidis DP, Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diab Res Clin Pract 1987;3:9–19
   PubMedGoogle Scholar
• Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010;8:828–837
   PubMed Web of Science ®Google Scholar
• Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers. Platelets 2012;23:565–570
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327–337
   PubMed Web of Science ®Google Scholar
• Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002;45:1034–1037
   PubMedGoogle Scholar
• Anfossi G, Russo I, Doronzo G, Trovati M. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets 2007;7:228–249
   PubMedGoogle Scholar
• Papanas N, Maltezos E. Oral antidiabetic agents: Anti-atherosclerotic properties beyond glucose lowering?. Curr Pharm Des 2009;15:3179–3192
   PubMed Web of Science ®Google Scholar
• Dolasık I, Sener SY, Celebı K, Aydın ZM, Korkmaz U, Canturk Z, The effect of metformin on mean platelet volume in dıabetıc patients. Platelets 2012 Apr 12. [Epub ahead of print]
   Google Scholar
• Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011;405:79–84
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ, Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Diseases. Curr Pharm Des 2012;18:5273–5293
   Google Scholar
• Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010;16:3808–3814
   PubMedGoogle Scholar
• Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003;9:2445–2464
   PubMed Web of Science ®Google Scholar
• Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003;54:507–530
   PubMed Web of Science ®Google Scholar
• Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, Singh S. Platelet indices in diabetes mellitus: Indicators of diabetic microvascular complications. Hematology 2011;16:86–89
   PubMed Web of Science ®Google Scholar
• Zhong ZL, Han M, Chen S. Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus. Int J Ophthalmol 2011;4:182–185
   PubMedGoogle Scholar
• Ünübol M, Ayhan M, Güney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. Platelets 2012;23:475–480
   PubMed Web of Science ®Google Scholar
• Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res 2009;41:585–593
   PubMedGoogle Scholar
• Harmsze AM, van Werkum JW, Moral F, Ten Berg JN, Hackeng CM, Klungel OH, de Boer A, Deneer VH. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98–102
   PubMed Web of Science ®Google Scholar
• Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS, Hong SP, Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2012 Aug 7. [Epub ahead of print]
   Google Scholar
• Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, O’Reilly M, Foley DP, Thompson CJ, Agha A, Smith D, et al. Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets 2012;23:439–446
   PubMed Web of Science ®Google Scholar